Document |
Document Title |
WO/2024/082009A1 |
This disclosure relates generally to methods and agents for treating cardiomyopathies. More particularly, the present disclosure relates to the use of CD14 antagonist antigen-binding molecules for treating a cardiomyopathy, including all...
|
WO/2024/084428A1 |
The present invention relates to a composition of substances effective in the prevention and/or treatment of cardiovascular system diseases, respiratory system diseases, immune system diseases, reproductive system diseases, nervous syste...
|
WO/2024/085700A1 |
The present invention relates to a composition for ameliorating, preventing, or treating myocardial damage caused by cardiotoxic drugs. The composition contains at least one selected from the group consisting of a Cirsium setidens extrac...
|
WO/2024/082008A1 |
This disclosure relates generally to methods and agents for treating arrhythmogenic cardiomyopathy (ACM). More particularly, the present disclosure relates to the use of CD14 antagonist antigen-binding molecules for treating ACM, includi...
|
WO/2024/086342A1 |
The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesic...
|
WO/2024/085558A1 |
The present invention relates to a composition for preventing or treating OSCAR-induced diseases, containing brivudine as an active ingredient, and a method for treating OSCAR-induced diseases, comprising the step of administering the co...
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
WO/2024/084390A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or periphe...
|
WO/2024/084421A1 |
The present invention provides methods of treatment, diagnostics, kits, and formulations for treating a subject having one or more genetic variations in an Actin alpha 2 (ACTA2) gene involving administering a therapeutically effective am...
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
WO/2024/083919A1 |
The present invention relates to use of inhibitors of the potassium channel Kv1.3 in therapeutic methods, in particular wherein the methods comprise administering the inhibitor to a subject at particular intervals.
|
WO/2024/085725A1 |
The present invention pertains to a novel compound derivative and a pharmacological use thereof and specifically to a novel 1,1-dioxo-1,2-benzisothiazole derivative or novel 3-citryl-1H-pyrazole derivatives possessing antiplatelet activi...
|
WO/2024/083861A1 |
The present invention relates to 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides derivatives according to formula (I) for use in the prevention and/or treatment of a disease or disorder selected from an autoimmune disease, organ transpla...
|
WO/2024/083937A2 |
The present invention relates to a method for imaging an anatomical structure in a subject in need thereof, comprising the following steps: a) providing an injectable pharmaceutical composition comprising, as a contrast agent, at least o...
|
WO/2024/086182A1 |
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or m...
|
WO/2024/082470A1 |
Provided are an alprostadil coupled nitric oxide donor compound or a pharmaceutically acceptable salt thereof. The medicine is decomposed into two active ingredients, namely alprostadil and nitric oxide, in vivo, the pharmacological acti...
|
WO/2024/086708A2 |
Disclosed herein are small molecule inhibitors of USP30 and their use in treating, ameliorating and/or preventing cardiomyopathy. Additionally, disclosed herein are methods of inhibiting the USP30 pathway and activity comprising contacti...
|
WO/2024/086531A1 |
The present invention provides methods for treating cardiac arrest in a subject. The methods involve administering to the subject a pharmaceutical composition comprising NANO2 dodecafluoropentane emulsion.
|
WO/2024/080361A1 |
The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
|
WO/2024/079360A1 |
The present invention relates to a composition or combined preparation which comprises L-carnitine and essential oils, specially essential oils from savory (Satureja hortensis), parsley (Petroselinum crispum) and /or rosemary (Rosmarinus...
|
WO/2024/080952A1 |
The present invention relates to usage of hydrogen peroxide compounds as active substance in elimination of diabetic retinopathy diseases and the symptoms resulting from these diseases, and pharmaceutical compositions comprising hydrogen...
|
WO/2024/080441A1 |
The present invention provides: a Paracoccus aminovorans BM109 strain (accession number KCTC 15059BP), which is excellent for removing trimethylamine (TMA) or trimethylamine N-oxide (TMAO); and a pharmaceutical composition for preventing...
|
WO/2024/080377A1 |
The present invention pertains to a method for detecting pulmonary hypertension, the method comprising step (I-1) and step (I-2), in that order. In step (I-1), the content of myosin light chain 9 (Myl9) protein in a biological sample der...
|
WO/2024/080931A1 |
The present disclosure describes anti-inflammatory properties of red blood cell extracellular vesicles, e.g., as mediated by heme, hemoglobin and/or phosphatidylserine content. The present disclosure describes technologies useful for the...
|
WO/2024/081611A1 |
Methods for treating heart failure are described herein. The treatment methods include administering a cardiac sarcomere activator (e.g., omecamtiv mecarbil, or a pharmaceutically acceptable salt and/or hydrate thereof) to a subject in n...
|
WO/2024/080356A1 |
[Problem] To provide a drug effective for the treatment of an intractable lymphatic disease and an intractable vascular disease. [Solution] Provided is a therapeutic agent for an intractable lymphatic disease and an intractable vascular ...
|
WO/2024/035884A8 |
Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: • a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically ...
|
WO/2024/078488A1 |
Disclosed in the present invention are a thiochroman derivative and a preparation method therefor and a use thereof. The structure of the thiochroman derivative is as shown in general formula (I), and the definition of each substituent i...
|
WO/2024/044542A3 |
Described are methods for treating diseases and disorders that can be mediated in part by a reduction in ANGPTL3 gene expression in a human subject in need of treatment, using pharmaceutical compositions that include ANGPTL3 RNAi agents....
|
WO/2024/080323A1 |
Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both. The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell in...
|
WO/2024/079324A1 |
The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said ...
|
WO/2024/081245A1 |
The present disclosure relates generally to methods of treating or preventing myocardial injury, or a condition associated with myocardial injury, in a mammal, wherein the method comprises administering at least one tissue differentiatio...
|
WO/2024/081925A1 |
Provided herein are lipid nanoparticle complex with nanoparticles cloaked in monocyte plasma membrane for effective delivery of drugs. Also provided herein are drug loaded lipid nanoparticle complex for inhibition of YAP/TAZ pathway and ...
|
WO/2024/078620A1 |
A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical comp...
|
WO/2024/078124A1 |
Provided in the present invention is the use of a TDGF1 gene in the preparation of a drug for treating aging-related diseases or reversing cell aging. Compared with the prior art, the present invention has the following advantages: the u...
|
WO/2024/079603A1 |
The present invention relates to novel pharmaceutical formulations given by the association of an inhibitor of histone methyltransferase activity and chemotherapeutic drugs for use in the treatment of cancer, in particular of colon cance...
|
WO/2024/081928A1 |
The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, h...
|
WO/2024/080661A1 |
The present invention relates to vMSC, which is a stem cell that is newly identified and has angiogenic properties. vMSCs cultured under specific culture conditions and identified, according to the present invention, are novel MSCs that ...
|
WO/2024/074116A1 |
The present invention relates to use of a compound represented by formula (I) or an ester thereof or a pharmaceutically acceptable salt thereof in the treatment of a disease accompanied by fibrosis.
|
WO/2024/075145A1 |
The present invention relates to a human dental pulp-derived stem cell population and culture supernatant thereof, a pharmaceutical composition comprising the stem cell population, and method for producing same. Specifically, the present...
|
WO/2024/075676A1 |
The present invention pertains to an agent that is for treating or preventing cerebral palsy, that contains dental pulp stem cells, and that is to be administered to a subject having a symptom of cerebral palsy.
|
WO/2024/075891A1 |
The present invention relates to a nitric oxide donor transporter (NODT) possessing low molecular weight levan. More specifically, a nitric oxide donor transporter composition includes low molecular weight levan with a molecular weight (...
|
WO/2024/075662A1 |
One purpose of the present disclosure is to provide a method for testing for the presence/absence of a stroke. The method for testing for the presence/absence of a stroke includes a step of measuring the presence/absence of at least on...
|
WO/2024/075139A1 |
The present application relates to an improved process for the preparation of finerenone and intermediates thereof, which is represented by the following structural formula-I.
|
WO/2024/074705A1 |
The present invention relates to a method of enhancing gene therapy by using an enzyme effective to degrade or digest and/or inhibit or reduce effector function of serum antibodies in the subject. More particularly, the subject is one th...
|
WO/2024/075815A1 |
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...
|
WO/2024/075017A1 |
The present invention relates to compounds useful for inhibiting calcification of aortic valves and to the treatment of diseases including aortic sclerosis and stenosis, and in particular to the use of the proton pump inhibitors includin...
|
WO/2024/076657A1 |
3 β-hydroxy-5-cholestenoic acid 3-sulfate (CA3S), a sulfated derivative of 3β-hydroxy-5-cholestenoic acid (CA), is provided. Both CA and CA3S have potent cholesterol and triglyceride lowering and anti-inflammatory activities. Methods o...
|
WO/2024/077310A1 |
A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases or conditions, and methods of using such preparations. The preparations may be a sublingual pill, an injection, ...
|
WO/2024/075675A1 |
The present invention relates to: a stem cell population derived from human milk tooth dental pulp, the stem cell population being characterized in that at least 90% of the stem cell population is CD117-negative, CD73-positive, CD90-posi...
|